Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib + R-CHOP in Previously Untreated DLBCL
NCT04263584Phase 2Completed
- Sponsor
- Universitätsklinikum Münster
- Start
- Jun 2020
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of copanlisib in diffuse large B-cell lymphoma (DLBCL), sponsored by Universitätsklinikum Münster. Primary endpoint: Progression-Free Survival up to 4 years. Started Jun 2020; status: completed.
02
Drugs
copanlisib
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04263584.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04263584.